2021 Annual Meeting | Industry Therapeutic Update from Bristol Myers Squibb: ZEPOSIA® (Ozanimod): A Once-Daily Oral Option for Patients with Relapsing Forms of MS
Program Materials Program Evaluations
No timeline events available at this time. |
Program Materials Program Evaluations
No timeline events available at this time. |